Active Biotech Future Growth
Future criteria checks 2/6
Active Biotech is forecast to grow earnings and revenue by 62.1% and 134.1% per annum respectively.
Key information
62.1%
Earnings growth rate
n/a
EPS growth rate
Biotechs earnings growth | 44.6% |
Revenue growth rate | 134.1% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 23 Oct 2024 |
Recent future growth updates
Recent updates
Here's Why We're A Bit Worried About Active Biotech's (STO:ACTI) Cash Burn Situation
Jun 05Is Active Biotech (STO:ACTI) In A Good Position To Invest In Growth?
Feb 19Active Biotech (STO:ACTI) Will Have To Spend Its Cash Wisely
Jul 27Here's Why Active Biotech (STO:ACTI) Must Use Its Cash Wisely
May 07Here's Why We're Not Too Worried About Active Biotech's (STO:ACTI) Cash Burn Situation
Nov 09We're Hopeful That Active Biotech (STO:ACTI) Will Use Its Cash Wisely
May 03We're Keeping An Eye On Active Biotech's (STO:ACTI) Cash Burn Rate
Jan 18Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 28 | -2 | N/A | -2 | 1 |
12/31/2025 | 9 | -27 | N/A | -27 | 1 |
12/31/2024 | N/A | -39 | N/A | -41 | 1 |
9/30/2024 | N/A | -42 | -40 | -40 | N/A |
6/30/2024 | N/A | -44 | -42 | -42 | N/A |
3/31/2024 | N/A | -45 | -45 | -45 | N/A |
12/31/2023 | N/A | -46 | -46 | -46 | N/A |
9/30/2023 | N/A | -48 | -48 | -48 | N/A |
6/30/2023 | N/A | -51 | -50 | -50 | N/A |
3/31/2023 | N/A | -54 | -51 | -51 | N/A |
12/31/2022 | N/A | -58 | -55 | -55 | N/A |
9/30/2022 | N/A | -60 | -57 | -57 | N/A |
6/30/2022 | N/A | -57 | -55 | -55 | N/A |
3/31/2022 | N/A | -56 | -53 | -53 | N/A |
12/31/2021 | N/A | -50 | -46 | -46 | N/A |
9/30/2021 | 6 | -38 | -35 | -35 | N/A |
6/30/2021 | 6 | -35 | -33 | -33 | N/A |
3/31/2021 | 6 | -32 | -29 | -29 | N/A |
12/31/2020 | 7 | -32 | -32 | -32 | N/A |
9/30/2020 | 1 | -39 | -38 | -38 | N/A |
6/30/2020 | 2 | -40 | -37 | -37 | N/A |
3/31/2020 | 3 | -36 | -40 | -40 | N/A |
12/31/2019 | 8 | -34 | -36 | -36 | N/A |
9/30/2019 | 12 | -32 | -35 | -35 | N/A |
6/30/2019 | 16 | -31 | -37 | -37 | N/A |
3/31/2019 | 21 | -35 | -38 | -38 | N/A |
12/31/2018 | 20 | -37 | -41 | -41 | N/A |
9/30/2018 | 21 | -88 | -41 | -41 | N/A |
6/30/2018 | 21 | -88 | N/A | -43 | N/A |
3/31/2018 | 20 | -103 | N/A | -44 | N/A |
12/31/2017 | 20 | -109 | N/A | -46 | N/A |
9/30/2017 | 22 | -63 | N/A | -52 | N/A |
6/30/2017 | 21 | -67 | N/A | -57 | N/A |
3/31/2017 | 20 | -59 | N/A | -61 | N/A |
12/31/2016 | 19 | -60 | N/A | -73 | N/A |
9/30/2016 | 17 | -86 | N/A | -86 | N/A |
6/30/2016 | 18 | -97 | N/A | -123 | N/A |
3/31/2016 | 17 | -152 | N/A | -187 | N/A |
12/31/2015 | 16 | -194 | N/A | -218 | N/A |
9/30/2015 | 14 | -210 | N/A | -245 | N/A |
6/30/2015 | 12 | -243 | N/A | -256 | N/A |
3/31/2015 | 11 | -229 | N/A | -243 | N/A |
12/31/2014 | 10 | -232 | N/A | -267 | N/A |
9/30/2014 | 12 | -257 | N/A | -157 | N/A |
6/30/2014 | 116 | -171 | N/A | -159 | N/A |
3/31/2014 | 116 | -194 | N/A | -170 | N/A |
12/31/2013 | 116 | -212 | N/A | -102 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ACTI is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ACTI is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ACTI is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ACTI's revenue (134.1% per year) is forecast to grow faster than the Swedish market (1.3% per year).
High Growth Revenue: ACTI's revenue (134.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ACTI's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/22 08:21 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Active Biotech AB (publ) is covered by 14 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Morten Larsen | ABG Sundal Collier |
Stefan Waldenlind | Carnegie Investment Bank AB |
Thomas Bowers | Danske Bank |